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Abstract: Immunotherapy is showing great promise for otherwise incurable cancers.  
Oncolytic viruses (OV), initially developed as direct cytotoxic agents, are now known to 
mediate their anti-tumour effects largely via activation of the immune system.  With regard to 
OV however, the immune system represents a double-edged sword because, as well as anti-
tumour responses, OV also stimulate anti-viral immune responses including the induction of 
anti-OV neutralizing antibodies.  Current dogma suggests that the presence of either pre-
existing anti-viral neutralizing antibodies in patients, or their development during viral 
therapy, is a barrier to systemic OV delivery rendering repeat systemic treatments ineffective.  
However, we have found that human monocytes loaded with pre-formed reovirus-antibody 
complexes, in which the reovirus is fully neutralized, deliver functional replicative reovirus to 
tumour cells resulting in their infection and lysis.  This delivery mechanism is mediated, at 
least in part, by antibody receptors (in particular FcγRIII) which mediate uptake and 
internalization of the reovirus/antibody complexes by the monocytes.  This finding has 
profound implications for oncolytic virotherapy and for the design of clinical OV treatment 
strategies in the future. 
Introduction 
The use of oncolytic virus (OV) therapy (a recognized form of immunotherapy) is 
progressing rapidly in the clinic, with confidence in the field increasing following FDA 
approval for the first agent in class, talimogene laherparepvec (T-Vec, a herpes Simplex virus 
encoding GM-CSF) to treat melanoma(1).  However, OV are not currently used as widely as 
other types of immunotherapy such as checkpoint inhibitors, possibly owing to the current 
perception that systemic administration will be limited by neutralizing antibodies (NAb).  
NAb may be present at baseline, for those viruses prevalent within the human population e.g. 
herpes simplex virus type 1, and mammalian orthoreovirus type 3 (herein referred to as 
“reovirus”), or they may arise following initial doses of OV therapy.  Such concerns 
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potentially limit systemic OV therapeutic strategies to a ‘one shot cure’ approach, whereby 
patients receive a single high dose of OV(2) or to direct OV injection into tumours.  Indeed, 
FDA approval for T-Vec is for intra-tumoural (i.t.) delivery only and while this route ensures 
viral access to the tumour, it is technically challenging and limits treatment to readily 
accessible tumours.  Systemic delivery has been shown to be safe, is broadly applicable in a 
clinical setting, and more suitable for targeting visceral or widespread metastatic disease.  We 
and others have investigated an alternative approach that circumvents NAb-mediated 
neutralization by delivering virus within carrier cells(3, 4).  This strategy is also clinically 
challenging but unexpectedly, developments from this work have indicated a potential 
positive role for NAb in OV therapy. 
We showed that i.t. delivery of single agent reovirus was effective as an anti-tumour therapy 
in mice, while systemically administered reovirus was relatively ineffective(5).  However, 
loading immune cells (T cells or dendritic cells) with reovirus ex vivo led to efficient 
systemic viral delivery to tumours, even in the presence of anti-reovirus NAb(3, 6).  
Following this, the results of a translational biological endpoint clinical trial (REO13) in 
patients with colorectal liver metastases, indicated that systemically delivered reovirus could 
access tumours and that functional virus was associated with immune cells in the blood but 
was not found in plasma(7).  These data suggest that, while free reovirus is rapidly 
neutralized by NAb in the serum following intravenous (i.v.) delivery, replication-competent 
virus can be transported to tumours via carriage by blood cells.  Consistent with this, pre-
conditioning mice with GM-CSF – to mobilize the myeloid compartment to the systemic 
circulation prior to i.v. reovirus treatment – resulted in effective therapy, the virus associating 
predominantly with CD11b+ cells in the blood(8).  Critically, GM-CSF pre-conditioning was 
only effective in reovirus-immunized mice with high serum anti-reoviral NAb, consistent 
with NAb contributing to therapeutic efficacy. 
In the current study, a human in vitro assay is described, in which monocytes are loaded with 
fully neutralized reovirus in the form of reovirus/neutralizing antibody (reoNAb) complexes 
and co-cultured with tumour cell targets.  Remarkably, whilst antibody-neutralized reovirus 
was unable to infect and kill tumour cells directly, it could be loaded onto human monocytes 
and delivered to melanoma cells in a functional/replicative form resulting in cell lysis.  After 
loading, antibody-neutralized reovirus was internalized by monocytes and processed to 
release infectious viral particles.  The internalization process involved surface Fc receptors 
(FcR), with FcγRIII expressed on non-classical monocytes playing a predominant role.  
These data have profound implications for the design of cancer therapy strategies and for 
mechanistically defining routes of viral dissemination and the initiation of adaptive immune 
responses which modulate infection.   
 
Results 
Reovirus is neutralized by IgG and IgA antibodies in patient-derived serum 
Serum was obtained from patients on a biological end-point clinical trial (REO13-BRAIN) in 
which they received i.v. reovirus (1 x 10
10
 TCID50) as monotherapy prior to surgical resection 
of brain tumours (primary or metastatic).  Blood samples were taken at least 7 days post 
reovirus treatment to ensure a high titre of anti-reoviral NAb and the serum was isolated.  A 
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standard neutralization assay indicated that serum from all patients was highly neutralizing 
towards reovirus (Fig. 1A), compared with serum from control donors (Fig. S1A).  To 
demonstrate the presence of reovirus-specific antibodies in the patient-derived serum, 
western blots of lysates from reovirus-infected cells (L929 cells or Mel-624 cells) were 
performed using patient-derived serum as the primary detection antibody and anti-human 
IgG, IgA or IgM secondary antibodies.  Both IgG and IgA antibodies in the serum recognized 
a range of reoviral proteins (Fig. 1B); IgM antibodies reactive to reovirus were not found.  
Depletion of IgG or IgA antibodies from the serum using specific anti-IgG or -IgA agarose 
beads showed that both isotypes contributed to reovirus neutralization, with IgG antibodies 
being predominant (Fig. 1C). 
It has been suggested that complement plays a role in the neutralization of reovirus(9). We 
therefore investigated this via heat inactivation (HI) of patient-derived serum. Figure 1D 
shows that HI-serum demonstrated equivalent neutralizing capacity to untreated serum, 
suggesting that heat-labile factors such as complement are not fundamental to reovirus 
neutralization in vitro.  Complement activity within patient-derived serum was verified (Fig. 
S1B). 
These data show that patients receiving i.v. therapeutic doses of reovirus develop a high anti-
reoviral antibody titre with IgG and IgA antibodies contributing to virus neutralization.  By 
contrast, complement does not appear to play a major role in reovirus inactivation. 
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Fig. 1. Reovirus is neutralized by IgG and IgA antibodies in patient-derived serum 
A) Reovirus neutralization assay.  Each colour corresponds to one serum sample, the control 
(no serum) is shown in black.  Solid lines show cultures containing reovirus and dotted lines 
those containing serum only.  B) Western blot of mock or reovirus-infected lysates using 
patient-derived serum as primary antibody and anti-human IgG/IgA secondary antibodies. 
Blots are representative of three patient sera.  C) IgG (red), IgA (blue) or both (purple) were 
depleted from serum and reovirus neutralization assays using depleted or whole sera (grey) 
were carried out, (control, black).  D) Reovirus neutralization assay using whole or heat-
inactivated (HI) serum.  Two different patients’ samples are shown in red or blue, whole 
serum (solid line) vs HI serum (dashed line); dotted lines show results in the presence of 
serum only (control, black). 
Formation of reovirus/neutralizing antibody complexes 
Our pre-clinical in vivo data led us to propose a model in which, following i.v. infusion, 
reovirus was rapidly bound by NAb to form reoNAb complexes which were delivered to 
tumours via monocytes(8).  Therefore, the formation of the proposed reoNAb complexes was 
verified using electron microscopy (EM).  Reovirus was allowed to adhere to EM grids which 
were then incubated with patient-derived serum or control serum from normal donors.  
Protein A gold labelling indicated the association of IgG with reovirus particles confirming 
the formation of reoNAb complexes (Fig. 2A).  There were significantly more gold particles 
associated with the reovirus following incubation with patient-derived serum (76%) than with 
control serum (40%) (Fig. 2A and B).  The presence of low level anti-reoviral NAb in control 
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serum is expected, as most people have had prior exposure to the virus(10-12); this data is 
also consistent with our previous clinical trial, in which NAb were present at baseline in 
patients, but significantly increased after i.v. reovirus administration(7). 
Thus, the anti-reoviral antibodies present in patient-derived serum can bind reovirus 
producing reoNAb complexes, such as would be formed following systemic reovirus therapy, 
especially on repeat administration. 
 
 
Fig. 2. Formation of reovirus/neutralizing antibody (reoNAb) complexes 
Reovirus was bound to copper grids prior to incubation with control or patient serum and 
labelled with protein A-gold (10 nm). Preparations were fixed, negatively stained with PTA 
and visualised at 52,000 X magnification by TEM.  A) Representative micrographs of 
labelled virions, demonstrating typical gold labelling patterns. Bar = 100 nm.  B&C) Gold 
labels on individual virions were quantified, n > 340 virions for each condition.  B) 
Percentage of virions having 0, 1-2, 3-4 or >5 gold labels associated per virion.  C) 
Proportion of virions being gold-labelled when pre-incubated with patient-derived serum 
(76%) vs control (40%); **p < 0.01 by χ2 test (χ2 = 92.9, cut-off 6.6 where df = 1). 
Monocytes loaded with pre-formed reoNAb complexes mediate killing of tumour cells 
In order to further develop the hypothesis that reoNAb can be delivered to tumours via 
monocytes in patients, the association of reovirus with human monocytes in the presence of 
neutralizing serum, was assessed.  Whole blood from normal donors was mixed with patient-
derived serum and reovirus was then added.  In the presence of NAb, virus was loaded onto 
CD14
+
 cells more efficiently than other immune cells (Fig. S2).  Next, we designed a human 
in vitro assay (Fig. 3A) in which human monocytes were loaded with either live non-
neutralized reovirus or pre-formed reoNAb complexes, and their ability to induce tumour cell 
death, was examined.  ReoNAb complexes were generated by incubating reovirus with a pre-
determined volume of neutralizing patient-derived serum at 37°C for 3 h.  The complexes or 
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non-neutralized reovirus were loaded onto isolated human monocytes which were then co-
cultured with melanoma target cells.  Melanoma targets were also treated with reovirus or 
reoNAb complexes in the absence of monocytes.  After 72 h, the cells were harvested and 
melanoma cell viability was determined by flow cytometry.  Mel-624 cells treated directly 
with reoNAb did not show any loss of viability compared with controls; however, when 
tumour cells were cultured with monocytes carrying reoNAb complexes, significant cell 
death was observed (Fig. 3B and C).  Monocytes loaded with non-neutralized reovirus 
induced higher levels of Mel-624 death than those loaded with reoNAb but the level of cell 
death induced by the latter was remarkable.  Mel-624 cells cultured with monocytes alone 
showed no any loss of viability, nor reduction in growth rate (Fig 3B and C). 
These results show that reovirus was fully neutralized within the reoNAb complexes and 
unable to infect melanoma targets directly, but following loading onto monocytes, the 
complexes induced tumour cell death. 
 
 
 
 
 
7 
 
 
Fig. 3. Monocytes loaded with pre-formed reoNAb complexes mediate killing of tumour 
cells 
A)  Schematic of the hand-off assay.  B) Representative microscopy images of Mel-624 cells 
treated with reoNAb complexes either directly (i) or following loading onto monocytes (ii) or 
co-cultured with monocytes alone (iii), scale bars = 400 µm.  C) Mel-624 cells were cultured 
for 72 h with reovirus or monocytes loaded ± reovirus or reoNAb at MOI 1 (MOI 3 wrt 
tumour cells) (i) or at varying MOI (ii).  Cells were harvested, stained with Live/Dead stain 
and examined by flow cytometry.  Monocytes were gated out and the percentage of viable 
tumour cells was determined.  Graphs show mean +SD from 3 independent experiments; 
****p = 0.00000094, **p = 0.0079, Student’s t-test. 
Infectious reovirus mediates the killing of tumour cells by reoNAb-loaded monocytes 
The observed tumour cell death could be mediated either by the monocytes themselves, 
following their activation by reoNAb complexes, or by release/transfer of infectious reovirus 
from the monocytes.  Therefore, reoNAb complexes were generated using either live or UV-
inactivated reovirus because both are able to activate monocytes (Fig. S3) but UV-inactivated 
reovirus is unable to infect and kill tumour cells directly(13).  Monocytes loaded with UV-
reoNAb complexes abrogated melanoma cell death following co-culture (Fig. 4A) suggesting 
that tumour cell death was due to reovirus infection and replication, rather than monocyte 
cytotoxicity.  In support of this, reovirus titre within monocyte-reoNAb and tumour cell co-
cultures increased over time (Fig. 4B), indicative of an on-going productive infection.  
Furthermore, blocking JAM-A (the known reovirus entry receptor) on the target melanoma 
cells, inhibited cell death (Fig. 4C), indicating that reovirus infection occurred via the normal 
entry route.  However, separation of monocytes and tumour targets with a transwell, 
abrogated cell death (Fig. S4), suggesting that initial hand-over from the monocytes was 
contact dependent and that JAM-A was required for later viral spread between tumour cells.  
Reovirus replication occurred predominantly within tumour cells rather than monocytes, as 
reovirus titre did not increase over time in monocytes loaded with reoNAb complexes (Fig. 
4D).  This is in contrast to our previous observations in myeloid-derived human dendritic 
cells, where reovirus replication does take place albeit at a relatively low level(3). 
These data indicate that fully antibody-neutralized reovirus can be loaded onto monocytes 
and delivered to tumour cells in a functional form, resulting in infection and oncolysis. 
8 
 
 
Fig. 4. Infectious reovirus mediates the killing of tumour cells by reoNAb-loaded 
monocytes 
A) Monocytes were loaded ± NAb or reoNAb complexes formed using live or UV-
inactivated reovirus (MOI 10) and co-cultured with Mel-624 cells.  Cell death was analysed 
by flow cytometry.  Graph shows mean +SD from 8 independent experiments; ****p = 
0.000000245, Student’s t-test.  B) Monocytes were loaded with reovirus or reoNAb (MOI 10) 
and added to Mel-624 cultures.  These were harvested at the times shown and viral titre 
determined by plaque assay. Graph shows mean +SD from four independent experiments; 
****p = 0.00000129, Student’s t-test.  C) Monocytes were loaded as in (B). Mel-624 target 
cells were pre-incubated for 30 min with isotype control or anti-JAM-A antibodies at 10 
µg/ml.  Percentage Mel-624 cell death at 96 h was determined.  Graph shows mean +SD from 
four independent donors; ***p = 0.00082, Student’s t-test.  D) Monocytes were loaded as in 
(B) and cultured for up to 48 h.  Samples were harvested at the times indicated and reovirus 
titre in the cells (i) and culture supernatants (ii) was determined by plaque assay.  Graphs 
show mean ±SD from 3 independent experiments. 
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ReoNAb complexes are internalized by monocytes prior to release of infectious virus 
Previously, we showed that live reovirus could be internalized by dendritic cells for delivery 
to tumour cells(6); in the current study, the fate of reoNAb complexes following their loading 
onto monocytes, was investigated.  EM demonstrated that reoNAb complexes were rapidly 
internalized by monocytes (Fig. 5A).  Free reovirus was also internalized by monocytes but 
this appeared less efficient than reoNAb internalization, as virus particles remained on the 
monocyte surface following loading with non-complexed reovirus, but not with reoNAb 
complexes (Fig. 5B). 
Having previously demonstrated that Fc receptors (FcR) were involved in the delivery of 
reovirus to tumours via monocytes in mice(8), their role in the delivery of reoNAb by human 
monocytes was examined.  Expression of FcγRIII (CD16), FcγRII (CD32), FcγRI (CD64) 
and FcαR (CD89) was confirmed by flow cytometry (Fig. S5) and the receptors were blocked 
prior to reoNAb loading.  Blocking FcγRI or FcγRII had little effect on the amount of 
reovirus loaded onto the monocytes or the delivery of reoNAb to tumour cells.  By contrast, 
blocking FcγRIII significantly reduced the level of reovirus loading onto monocytes (Fig. S6) 
and also melanoma cell death following co-culture (Fig. 5C).  This was noteworthy, since 
non-classical CD16
+
 monocytes represent only a small fraction (approx. 10%) of the 
monocytic population.  To confirm the significance of FcγRIII, CD16+ and CD16− monocytes 
were separated and their ability to deliver reoNAb to melanoma cells was compared.  We 
confirmed that non-classical CD16
+
 monocytes were more efficient in delivering reoNAb to 
induce melanoma cell death, whereas both classical and non-classical monocytes were able to 
deliver neat reovirus efficiently (Fig. 5D).  Furthermore, RNA sequencing data showed that 
FcγR mRNA levels were up-regulated in monocytes loaded with reoNAb complexes, FcγRIII 
showing the greatest increase (Fig. S7).  There appeared to be a potential role for the FcαR in 
mediating uptake of reoNAb by monocytes but this was not as marked as for FcγRIII (Fig. 
5C). 
These data show that FcR, particularly FcγRIII, are involved in the uptake of reoNAb 
complexes by monocytes, though they may not be the only mechanism of uptake since 
tumour cell death was not completely abrogated by blocking these receptors. 
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Fig. 5. ReoNAb complexes are internalized by monocytes prior to release of infectious 
virus 
Negatively-selected monocytes were loaded with reoNAb (A) or reovirus (B) then washed, 
fixed and processed as described in M&M.  TEM sections were viewed with an FEI Tecnai 
TWIN microscope at 120kV.  C) Monocytes were pre-incubated with anti-FcγR antibodies or 
anti-FcαR human recombinant antibody, then loaded with reoNAb and added to Mel-624 
targets; cell death was assessed by flow cytometry after 72 h.  Mean +SD from four donors 
are shown; **p = 0.0089, Student’s t-test.  D) CD16+ or CD16− monocytes were selected 
from PBMC, loaded with reovirus or reoNAb, washed and added to Mel-624 targets for 72 h. 
The proportion of dead Mel-624 cells was determined by flow cytometry.  Graph shows 
mean +SD from four donors; *p = 0.036, Student’s t-test. 
The efficacy of reoNAb complexes is not restricted to melanoma cells and is applicable to 
other OV 
In order to show that the delivery of reoNAb complexes to tumour cells via monocytes was 
not melanoma-specific, tumour cells of other histological types were tested.  ReoNAb 
complexes loaded onto monocytes were delivered effectively to colorectal, prostate and 
ovarian tumour cells, resulting in significant cell death (Fig. 6A).  In addition, we have 
previously shown that pre-conditioning with GM-CSF, followed by systemic reovirus 
treatment, enhances survival in reovirus-immunized mice bearing TC2 (prostate) tumours(8) 
or intra-cranial GL-261 (glioma) tumours(14).  Thus the therapeutic efficacy of anti-reoviral 
NAb are likely to be broadly applicable over a range of tumour types. 
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Given the number of OV currently under investigation as therapeutic agents, it would be 
valuable to establish whether other anti-OV antibodies can contribute to therapy.  Serum or 
pleural fluid was obtained from patients undergoing clinical trials with Coxsackievirus 
(CVA-21) and herpes simplex virus (HSV1716) and CVA/NAb and HSV/NAb complexes 
were generated.  Both of these OV/NAb complexes were ineffective when cultured directly 
with melanoma targets, indicating complete neutralization of the viruses.  However, 
following loading onto monocytes, CVA/NAb were comparable to reoNAb in mediating 
tumour cell death, while by contrast, HSV/NAb were ineffective (Fig. 6B).  These findings 
show that the contribution of anti-OV antibodies to oncolytic virotherapy, while not being 
universally applicable, is not specific to reovirus. 
 
 
 
Fig. 6. The efficacy of reoNAb complexes is not restricted to melanoma cells and is 
applicable to other OV 
A) Target cells were treated with medium, reoNAb complexes or reoNAb loaded monocytes, 
and cell death was assessed by flow cytometry after 72 h.  Graph shows mean +SD from 
three independent experiments; Mel-624 **p = 0.0087, HCT116 **p = 0.0047, PC3 *p = 
0.0373, SKOV3 ***p = 0.0007, Student’s t-test.  B) Virus-neutralizing antibody complexes 
(virusNAb) were formed using matched OV and patient-derived NAb. These were co-
cultured with Mel-624 targets. Mel-624 cell death was assessed at 72 h by flow cytometry.  
Graph shows mean +SD from at least three independent experiments; reovirus **p = 0.0038, 
CVA21 ***p = 0.0008, ns = not significant, Student’s t-test. 
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ReoNAb complexes deliver functional reovirus to tumours in vivo 
Although we have demonstrated the importance of anti-reoviral antibodies in the therapeutic 
response to i.v. reovirus therapy following GM-CSF pre-conditioning in mice(8), we have not 
shown that pre-formed reoNAb complexes can mediate delivery of functional reovirus to 
tumour-bearing mice.  Therefore, we used serum from mice that had been pre-immunized 
against reovirus – high anti-reoviral NAb (Fig. S8) – to generate reoNAb complexes.  These 
were injected i.v., with or without prior GM-CSF conditioning, into tumour-bearing mice.  
After three days the tumours were harvested and examined for functional reovirus by plaque 
assay.  Functional reovirus was detectable within the tumours of all of the mice that had 
received GM-CSF pre-conditioning, but in only two of four mice that did not receive GM-
CSF (Fig. 7A).  This indicates that in spite of complete antibody-neutralization, functional 
reovirus can access tumours in vivo and is consistent with our previous data showing that i.v. 
administration of reovirus was not therapeutic in tumour-bearing mice unless the mice had 
been pre-conditioned with GM-CSF(8).  Furthermore, administration of GM-CSF followed 
by reoNAb complexes delayed tumour growth and increased survival in tumour-bearing, 
reovirus-naive mice (Fig 7B&C).  This therapeutic effect was less than we had previously 
seen following GM-CSF/reovirus treatment in reovirus-immunized mice(8) and suggests that 
as well as contributing to reoviral delivery to tumours, systemic anti-reoviral Ab have an 
additional role in mediating therapy. 
ReoNAb complexes formed using an anti-reoviral monoclonal antibody were delivered as 
efficiently as those generated using serum from reovirus-immunized mice (Fig 7A), further 
supporting our hypothesis that this is an antibody-mediated process rather than being 
dependant on other serum factors.  Moreover, delivery was enhanced by using a combination 
of monoclonal antibodies rather than a single one.  This has implications for therapy as it 
suggests the possibility of improving therapeutic outcome by manipulation of the antibodies 
coating the reovirus. 
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Fig. 7. ReoNAb complexes deliver functional reovirus to tumours in vivo 
A) Mice bearing 7 d established B16 tumours received 1 cycle of GM-CSF/reoNAb.  
ReoNAb were generated using either anti-reovirus mouse serum, a single anti-reovirus 
monoclonal antibody (G5), or a combination of monoclonal antibodies (combo).  Tumours 
were harvested on day 14 and viral titre determined by plaque assay.  Graph shows mean 
±SD pfu/mg of tumour; *p = 0.045, one way ANOVA.  B&C) Mice bearing 3 d B16 tumours 
were treated as above.  Mice were sacrificed when tumours reached 1 cm in diameter; GM-
CSF/reoNAb vs control p = 0.022, log rank test. 
 
Discussion 
Intravenous delivery of an oncolytic virus represents not only the optimal means of accessing 
disseminated neoplastic tissue, but is also likely to be the most practical way of stimulating a 
systemic response from the immune system. However, this route of infusion is often 
eschewed in favour of more local methods given the many ‘hurdles’ to viral persistence 
present in the vasculature, one prominent perceived obstacle being neutralizing antibodies.  
As sero-prevalence for reovirus is common, in most individuals any i.v.-administered virus 
will encounter low-level NAb.  A number of early-phase clinical trials have involved the 
administration of OV as a large i.v. bolus. Seen in the context of a pre-existing low-level 
immunity to the virus, these therapeutic infusions represent a re-exposure to abundant viral 
antigens and result in a large-scale anamnestic response. This is characterised by the rapid 
generation of antiviral antibodies in circulation at very high titre(15, 16), which is considered 
to preclude further therapeutic i.v. doses. 
Our previous work, which focused on potentiating the delivery of reovirus to tumours by 
evasion of the anti-reoviral NAb response, unexpectedly uncovered a role for these antibodies 
in the therapeutic response(8).  Here, we have further investigated the therapeutic potential of 
NAb, specifically in the form of reoNAb complexes where the virus is fully neutralized and 
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unable to infect susceptible tumour cells.  The source of anti-reoviral NAb was serum from 
patients on the REO13-BRAIN clinical trial.  All patients had high anti-reovirus NAb, 
comprising IgG and IgA isotypes, both contributing to reovirus neutralization (Fig. 1), with 
no evidence for involvement of the complement system. This contradicts a recent study in 
which an inhibitor of the complement C3 molecule precluded reovirus neutralization in 
plasma(9). The basis for this disparity is unclear. We employed a different strategy of 
disabling complement (HI vs inhibitor) and output method (MTT assay vs plaque assay), and 
used serum rather than anticoagulant-treated plasma; all of which could contribute to the 
difference in outcome. 
ReoNAb complexes were generated by incubating reovirus with a neutralizing volume of 
serum and their formation was confirmed by EM (Fig. 2).  Reovirus neutralization was 
confirmed by incubating the reoNAb complexes with susceptible melanoma target cells; no 
cell death was observed, indicating that the virus was fully neutralized and unable to infect 
the cells.  However, following loading onto isolated human monocytes, the reovirus within 
the complexes could be transferred to melanoma targets to induce target cell death (Fig. 3).  
The mechanism by which the reoNAb complexes are processed by monocytes and transferred 
to tumour cells is currently the subject of further investigation in our laboratory but we have 
shown that it involves their internalization by the monocytes, this being partly dependent on 
FcγRIII (Fig. 5).  This was surprising as non-classical monocytes expressing FcγRIII form 
the minor subset of peripheral blood monocytes but we have demonstrated that, within a 
mixed population, their contribution to reoNAb transport is proportionally larger than that of 
classical monocytes.  Nevertheless, there appears to be some contribution by classical 
monocytes, which may depend on an alternative mechanism of uptake.  In contrast to human 
myeloid-derived dendritic cells, which support low level replication, reovirus does not appear 
to replicate within freshly isolated human monocytes, indicating that viral amplification does 
not occur following internalization.  The role of FcR in reoNAb transport suggests that NK 
cells and neutrophils, which express FcγRIII, may also play a role in reoNAb transport. 
We have examined the delivery of reoNAb complexes to other tumour cell lines and found 
that it is not restricted to melanoma (Fig. 6A), suggesting the wide applicability of our 
findings in influencing treatment design for many cancer patients.  Furthermore, we have 
demonstrated that the phenomenon of reoNAb delivery is not reovirus-specific because 
CVA/NAb complexes are delivered to tumour cells by monocytes in a similar manner, 
although HSV/NAb are not, suggesting that specific aspects of virus physiology may 
determine applicability (Fig. 6B).  It is unclear which aspects govern the delivery of OV via 
NAb complexes but given our observations with reovirus, CVA and HSV1716, one 
possibility is the presence or otherwise of a viral envelope.  However, a pre-existing immune 
response improves the therapeutic efficacy of Newcastle Disease virus (Jacob Ricca, abstract 
O15, SITC 2016) and Maraba virus(17), suggesting a possible role for OV/NAb delivery via 
monocytes for both of these enveloped viruses and therefore we postulate that delivery of 
OV/NAb complexes might be restricted to small RNA viruses rather than those with DNA 
genomes. 
Finally, we have demonstrated that following i.v. delivery of reoNAb complexes to tumour-
bearing mice, functional reovirus can be retrieved from the tumours (Fig. 7), supporting our 
hypothesis that i.v. reovirus therapy in pre-immunized mice results in the rapid formation of 
reoNAb complexes in vivo which are then delivered to tumours via monocytes(8).  Although 
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we know that following i.v. delivery, reovirus is rapidly neutralized by NAb, this cannot be 
instantaneous and it is possible that transport of non-neutralized reovirus by monocytes was 
responsible for viral delivery to the tumours.  Although we have not ruled out this possibility, 
we have demonstrated that fully neutralized reovirus in the form of reoNAb can be delivered 
in a functional form in vivo.  Furthermore, tumour-bearing mice treated with GM-CSF 
followed by pre-formed reoNAb have delayed tumour growth and prolonged survival 
compared to controls, indicating that reoNAb have therapeutic potential.  The therapeutic 
effect of reoNAb following GM-CSF pre-conditioning in naive mice, was less than we had 
previously shown using non-complexed reovirus in reovirus-immunized mice.  Thus the 
enhanced therapeutic effect of a pre-existing anti-reoviral immune response(8) can only 
partly be mediated by reoNAb complexes formed after i.v. reovirus treatment and other 
immune mechanisms (e.g. ADCC or reovirus-specific CTL) must be involved.  The data also 
suggest that reovirus therapy could be enhanced by manipulation of the antibodies bound to 
the virus.  Whilst a single neutralizing monoclonal antibody was as effective as anti-reoviral 
serum in mediating delivery of functional virus to tumours, a combination of monoclonal 
antibodies was significantly more effective (Fig 7A).  This suggests the possibility of pre-
formed reoNAb complexes as a novel therapeutic in which the antibodies are selected to 
provide the most efficient viral delivery to tumours.  
To our knowledge, this reactivation and release of antibody-neutralized virus by human 
monocytes has not previously been described and although it may appear counter-intuitive, 
there is some related evidence supporting our observations.  Firstly, dendritic cells release 
macropinocytosed Ag in a native unprocessed form from late endocytic compartments to 
stimulate B cells(18) indicating that not all internalized Ag is necessarily degraded by 
myeloid cells.  With regard to FcR involvement, Ab-neutralized adenovirus has been found to 
mediate gene transfer via an FcR dependent mechanism(19), though there was no viral 
release from the cells.  The reports most closely related to our findings are of antibody-
dependent enhancement (ADE) of infection.  This occurs during infection with Flaviviruses 
including dengue virus, whereby patients previously exposed to another dengue virus 
serotype form non-neutralizing-Ab-virus complexes which are taken up by FcR expressing 
cells (including monocytes) resulting in enhanced virus infection(20, 21).  ADE has also been 
reported for measles virus(22), another OV currently undergoing clinical trials.  However, in 
contrast to our observations, ADE depends on the cross-reactivity of non-neutralizing 
antibodies whereas our research highlights a hitherto unidentified role for neutralizing 
antibodies in mediating viral dissemination. 
In conclusion, we have demonstrated a highly novel phenomenon whereby fully antibody-
neutralized reovirus is internalized and processed by monocytes resulting in transfer of 
infectious virions that are able to infect and destroy tumour cells.  Taken together with our 
previous data indicating the positive involvement of anti-viral NAb(8), we suggest that this 
indicates a paradigm shift with respect to the current dogma regarding the ‘problems’ of anti-
viral NAb for OV therapy. That this observation is not specific to reovirus but is likely 
widely applicable to other OV, increases the significance of our findings.  Further research is 
needed to identify the factors that determine which OV can be delivered in this manner, as 
this will have a significant impact on the design of future clinical trials. 
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Materials and Methods 
Cell lines 
Cell lines were grown in DMEM or RPMI containing L-glutamine (Sigma) supplemented 
with 10% (v/v) heat-inactivated foetal calf serum (Life Technologies).  Cell lines were 
monitored routinely and found to be free of Mycoplasma infection. 
Viruses 
Reovirus Type 3 Dearing strain (Reolysin™) supplied by Oncolytics Biotech (Calgary, 
Canada); Coxsackievirus type A21 (CVA21, CAVATAK™) supplied by Viralytics (Sydney, 
Australia); Herpes Simplex virus 1716 (HSV1716, Seprehvir™) supplied by Virttu Biologics 
(Glasgow, UK).  Stock virus concentrations were determined by plaque assay on L929 
(reovirus), SK-Mel-28 (CVA21), Vero (HSV1716) cells.  UV-inactivation of reovirus was by 
2 min UV-irradiation of 100 µl aliquots in a 96-well plate, using a Stratalinker UV 1800 
(Stratagene); confirmed to be non-replicative by plaque assay. 
Patient-derived serum/pleural fluid 
Serum was obtained with ethical approval and consent from patients enrolled in clinical 
trials: for reovirus, the REO13-brain trial (ISRCTN70443973); for CVA21, the STORM trial 
(NCT02043665).  Blood was collected into tubes containing a clotting activator.  Samples 
were centrifuged at 2000 rpm for 10 min, the serum fraction harvested and stored at −70°C.  
Pleural fluid from patients treated with intrapleural HSV1716 (trial NCT01721018) was a gift 
from Joe Conner (Virttu Biologics).  Where required, serum was heat-inactivated by 
incubation in a water-bath at 56°C for 30 min. 
Complement activity assay 
Untreated or heat-inactivated serum samples were diluted in Gelatin Veronal Buffered 
(GVB++) Saline (Sigma).  Increasing volumes were added to vortexed sheep erythrocytes 
(Stratech) and GVB++ to a final volume of 1.5 ml according to the manufacturer’s protocol 
(CompTech).  Negative and positive controls were included to give background and 100% 
lysis values, respectively.  Tubes were placed in a 37°C water bath for 60 min and cells were 
re-suspended every 10 min then placed on ice and centrifuged for 3 min at 800 g.  
Supernatants were transferred to a Maxisorp 96 well plate and absorbance at 540 nm was 
determined using a Multiskan EX plate reader (Thermo). 
Percentage lysis = (OD test sample – OD blank)/(OD total lysis – OD blank) x 100. 
Neutralization assay 
Halving dilutions of serum or pleural fluid were added to 80% confluent monolayers of 
susceptible cells (see above) in a 96-well plate. Virus was added to achieve an MOI 0.05 
(reovirus and CVA21) or MOI 1 (HSV1716).  Cell survival was assayed at 72 h by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Preparation of monocytes 
PBMC were isolated from healthy donor leukapheresis cones by density-gradient 
centrifugation on lymphoprep (Axis Shield).  CD14
+
 monocytes were isolated from PBMC 
by positive selection with anti-CD14 Microbeads; for EM, monocytes were negatively 
selected from PBMC using the Human Pan Monocyte Isolation kit; CD16
+
 monocytes were 
selected from PBMC using the CD16
+
 Monocyte Isolation kit (all kits from Miltenyi). 
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Preparation of OV/NAb complexes 
For in vitro assays, OV was incubated with a pre-determined neutralizing volume of patient-
derived serum (reovirus, CVA21) or pleural fluid (HSV1716) for 2-3 h at 37C.  For in vivo 
experiments, the serum was obtained from mice pre-immunized i.p. with two doses of 2 x 10
7
 
pfu reovirus seven days apart; serum was obtained seven days after the second immunization.  
The anti-reoviral monoclonal antibodies used to generate the complexes were obtained from 
DSHB (Iowa) and were clones G5, 10F6, 8H6, 10G10, 10C1.  Pre-determined neutralizing 
volumes were mixed with the virus and incubated for 2-3 h at 37C. 
Co-culture assay 
OV, NAb or OVNAb complexes were added to isolated monocytes and incubated at 4°C for 
2-3 h. Cells were washed 3x in PBS, re-suspended in RPMI and added to target cells either 
directly or separated by a 1 µm transwell (Greiner Bio-one) at a ratio of 3:1 
(monocytes:targets).  They were co-cultured at 37°C for 72 h, unless stated otherwise.  Cell 
viability was analysed by flow cytometry using a LiveDead® stain (Thermo) according to the 
manufacturer’s instructions.  Where indicated, Jam-A on the target cells was blocked by pre-
incubating with 10 µg/ml anti-Jam-A antibody, clone J10.4 (Santa-Cruz) for 30 min at 37°C.  
FcR on the monocytes were blocked by pre-treatment with 100 µg/ml anti-FcγR F(ab’)2 
antibodies (Ancell) or anti-FcαR human recombinant antibody (Miltenyi) at 4°C for 45 
minutes.   
Depletion of antibody isotypes from serum 
Serum was diluted 1:1 in PBS and incubated for 90 min at RT with agarose bead-conjugated 
antibodies specific for the human γ- or α-chain (Sigma).  The samples were then centrifuged 
to remove beads (3,000 g, 15 s) and the supernatant harvested.  Antibody depletion was 
confirmed by enzyme-linked immunosorbent assay (ELISA) using human IgG/IgA ELISA 
kits (Mabtech). 
Western Blot 
Lysates from reovirus-infected (MOI=1) Mel-624 or L929 cells (20 µg protein per lane) were 
separated by SDS-PAGE electrophoresis, transferred to nitrocellulose, blocked in 5% milk 
and probed using patient-derived serum (1:200 dilution) as primary antibody.  Blots were 
washed 3x in PBST, and incubated with an HRP-conjugated goat secondary antibody against 
human IgG, IgA or IgM (all Thermo), diluted 1:5,000 in 5% milk/PBST.  After a further 
three washes, blots were visualised with the chemiluminescent SuperSignal West Pico 
substrate (Thermo) on a Gel Doc XR system using Image Lab software (Bio-Rad). 
Immunoprecipitation of reovirus 
Reovirus was added to serum at a 1:5 (v/v) ratio and incubated at 37°C for 3 h. 1.5 ml 
Eppendorf tubes were blocked with 3% (w/v) bovine serum albumin for 1 h at 4°C, prior to 
the addition of reovirus-antibody samples. Pre-washed protein A resin beads (GenScript) in 
excess were mixed with samples and allowed to bind for 2 h at 4°C on a rotator. Samples 
were centrifuged (400 g, 2 min), washed 4x in 0.1% (v/v) Triton-X in PBS, then boiled 
(95°C, 5 min) in loading buffer to dissociate IgG from beads, and centrifuged (13,200 g, 2 
min) to yield supernatant for analysis. 
Electron Microscopy 
Visualization of reoNAb complexes.  Reovirus stock was dropped onto Veco 100-mesh 
copper grids (Electron Microscopy Sciences) and allowed to attach (RT, 5 minutes). Grids 
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were washed 4x in PBS prior to incubation (90 min, RT) with patient-derived serum or 
control serum, diluted 1:10 in PBS. After 4x washes in PBS, grids were incubated with 
protein A-conjugated 10 nm gold particles (1:300 in PBS + 1% v/v BSA) for 30 min at RT.  
After washing (4x PBS, 4x ddH2O), grids were fixed for 1 h with 1.5% glutaraldehyde in 0.1 
M sodium cacodylate. After 4x washes in ddH2O, grids were negatively stained with 1% 
phosphotungstic acid for 30 s, then blotted and air-dried. Grids were visualised using an FEI 
Tecnai TWIN microscope at 120 kV (magnification 52,000 X). 
Visualization of reoNAb-loaded monocytes.   
Negatively selected monocytes were loaded, with either live reovirus or reoNAb at MOI 50, 
washed twice with ice-cold PBS and re-suspended in 2% (v/v) PFA + 0.2% (v/v) 
glutaraldehyde in 0.1 M PHEM buffer; they were then pelleted, re-suspended in storage 
buffer (0.5% w/v PFA in 0.1 M PHEM) and kept at 4°C prior to processing.  Cells were post-
fixed for 1 h at 4°C with 1% (w/v) osmium tetroxide in 0.1 M sodium cacodylate buffer, 
rinsed in buffer and re-suspended in 2% (w/v) agar.  0.5-1 mm
3
 blocks were cut, dehydrated 
in ethanol followed by propylene oxide, then infiltrated with ascending ratios of LX-112 
Epon resin/propylene oxide (1 h each) finishing in pure resin.  Resin was polymerised at 
70°C for 48 h, and 80 nm sections were cut using an Ultracut S microtome (Leica).  TEM 
sections were viewed using an FEI Tecnai TWIN microscope at 120 kV. 
RNA sequencing 
Monocytes were loaded with live reovirus or reoNAb (MOI 10), re-suspended in complete 
RPMI and cultured for 24 h, then harvested, RNA extracted using the RNeasy mini kit 
(Qiagen) according to manufacturer’s instructions and treated with DNase I.  mRNA libraries 
were prepared using the NEBNext Ultra Directional RNA library prep kit (New England 
BioLabs) and sequenced using the HiSeq 2500 system (Illumina).  Fastq files were analysed 
in R using the DEseq2 package (Bioconductor). 
In vivo experiments 
These were carried out at the University of Leeds or the Mayo Clinic, Rochester MN.  All in 
vivo studies were approved by either the Leeds local ethics committee and UK Home Office 
or the Mayo IACUC.  Six- to eight-week-old female C57Bl/6 mice were purchased from 
Charles River Laboratories (Margate, Kent) or Jackson Laboratories (Bar Harbor, Maine).  
Mice were challenged subcutaneously with 5 × 10
5
 B16 melanoma cells.  One treatment 
cycle of GM-CSF/reoNAb = 300 ng GM-CSF i.p. on 3 consecutive days followed by 2 x 10
7
 
pfu reoNAb complexes i.v on the following two days.  Reovirus delivery: one cycle of 
treatment was given to mice bearing 7 d established tumours.  Tumours were harvested on 
day 14, weighed and divided for analysis by plaque assay and qRT-PCR.  For plaque assay, 
the tumour sample was homogenized and subjected to 3 cycles of freeze/thaw, then clarified 
by centrifugation and viral titre determined by plaque assay on L929 cells.  For qRT-PCR, 
RNA was extracted using the RNeasy mini kit (Qiagen) according to manufacturer’s 
instructions.  cDNA synthesis was carried out using the SuperScript IV first-strand system 
(Thermo) according to manufacturer’s instructions.  Analysis was conducted using the ABI 
7500 real-time system (Applied Biosystems) and reovirus S3 copy number was quantified 
using the ΔΔCT method against GAPDH as comparator.  Therapy studies: mice bearing 3 d 
established tumours were given one treatment cycle as described above.  Tumours were 
measured three times per week, and mice were euthanized when tumours reached 1 cm 
diameter. 
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Statistical Analysis 
Data were analysed using GraphPad Prism software.  Significance was evaluated using 
Student’s t-test (multiple comparisons with Holm-Sidak correction), chi-squared test or one-
way ANOVA (with Tukey correction) as appropriate, with p < 0.05 considered significant.  
Survival analysis was carried out using the log rank test. 
Supplementary materials 
Fig. S1. Patient-derived serum is highly neutralizing 
Fig. S2. Patient-derived neutralizing antibodies favour routing of virus to CD14+ cells 
in whole blood 
Fig. S3. UV-inactivated reovirus induces monocyte activation 
Fig. S4. Hand-off of reoNAb by monocytes is contact-dependent 
Fig. S5. Expression of Fc receptors on primary human monocytes 
Fig. S6. FcγRIII receptor blockade impairs reo/NAb loading of monocytes 
Fig. S7. Reo-NAb induce increased FcR RNA levels in monocytes 
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